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Neoadjuvant chemotherapy (NACT) is a term originally used to describe the administration of chemotherapy preoperatively before
surgery. The original rationale for administering NACT or so-called induction chemotherapy to shrink or downstage a locally
advanced tumour, and thereby facilitate more effective local treatment with surgery or radiotherapy, has been extended with the
introduction of more effective combinations of chemotherapy to include reducing the risks of metastatic disease. It seems logical that
survival could be lengthened, or organ preservation rates increased in resectable tumours by NACT. In rectal cancer NACT is being
increasingly used in locally advanced and nonmetastatic unresectable tumours. Randomised studies in advanced colorectal cancer
show high response rates to combination cytotoxic therapy. This evidence of efficacy coupled with the introduction of novel
molecular targeted therapies (such as Bevacizumab and Cetuximab), and long waiting times for radiotherapy have rekindled an
interest in delivering NACT in locally advanced rectal cancer. In contrast, this enthusiasm is currently waning in other sites such as
head and neck and nasopharynx cancer where traditionally NACT has been used. So, is NACT in rectal cancer a real advance or just
history repeating itself? In this review, we aimed to explore the advantages and disadvantages of the separate approaches of
neoadjuvant, concurrent and consolidation chemotherapy in locally advanced rectal cancer, drawing on theoretical principles,
preclinical studies and clinical experience both in rectal cancer and other disease sites. Neoadjuvant chemotherapy may improve
outcome in terms of disease-free or overall survival in selected groups in some disease sites, but this strategy has not been shown to
be associated with better outcomes than postoperative adjuvant chemotherapy. In particular, there is insufficient data in rectal cancer.
The evidence for benefit is strongest when NACT is administered before surgical resection. In contrast, the data in favour of NACT
before radiation or chemoradiation (CRT) is inconclusive, despite the suggestion that response to induction chemotherapy can
predict response to subsequent radiotherapy. The observation that spectacular responses to chemotherapy before radical
radiotherapy did not result in improved survival, was noted 25 years ago. However, multiple trials in head and neck cancer,
nasopharyngeal cancer, non-small-cell lung cancer, small-cell lung cancer and cervical cancer do not support the routine use of NACT
either as an alternative, or as additional benefit to CRT. The addition of NACT does not appear to enhance local control over
concurrent CRT or radiotherapy alone. Neoadjuvant chemotherapy before CRT or radiation should be used with caution, and only
in the context of clinical trials. The evidence base suggests that concurrent CRT with early positioning of radiotherapy appears the
best option for patients with locally advanced rectal cancer and in all disease sites where radiation is the primary local therapy.
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The term neoadjuvant chemotherapy (NACT) was suggested over
20 years ago (Frei, 1982). Given that tumour size is a predictor of
outcome in most disease sites, NACT has often been proposed with
the aim or reducing the gross tumour burden before surgery,
radiation or chemoradiation (CRT). The original hypothesis
proposed that neoadjuvant cytotoxic chemotherapy could shrink
a locally advanced tumour, and thereby allow more effective local
therapy. Reducing the size of a tumour may facilitate a curative
surgical resection. Also, in general, smaller cancers may be more
oxygenated, and hence easier to control with radiation (Fletcher,
1980, 1984). Since then, the breadth of treatment possibilities has
been extended as more effective combinations of cytotoxic
chemotherapy and more recently new molecular targets that
potentially reduce the risks of metastatic disease have been
introduced.
In stages II and III of rectal cancer the optimal multimodality
management remains an increasing challenge. Surgery remains the
mainstay of treatment, but a high risk of local recurrence and poor
survival (40–55% at 5 years) has been reported even for patients
with mobile/resectable rectal cancer despite a curative resection
and postoperative CRT (Tepper et al, 2002). Despite improved
local surgical and radiotherapeutic techniques, locoregional
relapse is now exceeded by the rate of development of systemic
metastases. The Dutch rectal cancer study, CKVO 95–04, which
randomised between surgery alone and short-course preoperative
radiotherapy followed by immediate surgery, found local regional
control improved from 91.6 to 97.6% at 2 years with preoperative
radiotherapy (Kapiteijn et al, 2001). However, the rate of
metastatic disease was 18% in both arms at 2 years. Despite low Revised 16 December 2005; accepted 16 December 2005
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srates of local recurrence, 25–35% of patients with rectal cancer still
eventually die from metastatic disease. In patients with unresect-
able disease (Frykholm et al, 2001) both local control and
metastatic disease remain issues.
There is increasing enthusiasm for preoperative CRT in the
management of rectal cancer. The advantage of using radiotherapy
in the preoperative setting includes the potential to increase the
likelihood of a R0 resection; to reduce the risk of tumour seeding;
less acute toxicity; and enhanced radio-sensitivity because of better
oxygenated cells as opposed to hypoxic cells in scar tissue; and an
improved chance of sphincter preservation achieved by down-
staging the tumour. Finally, compliance to treatment may be more
easily achieved in the preoperative compared to the postoperative
setting.
Recent data from studies in advanced/metastatic colorectal
cancer show high response rates to combination cytotoxic
chemotherapy (Cassata et al, 2001; Cassidy et al, 2004). Three
drug combinations of 5-fluorouracil (5FU), oxaliplatin and
irinotecan may now give even higher response rates in the region
of 75% (Calvo, 2002; Falcone et al, 2002; Ychou et al, 2003). This
evidence of efficacy coupled with the introduction of novel
molecular targeted therapies (Saltz et al, 2002; Cho et al, 2003;
Cunningham et al, 2004; Tabernero et al, 2004), has heightened an
interest in delivering NACT in locally advanced rectal cancer.
Where there are delays (as in the UK) in starting CRT or RT,
because of a lack of resources, the use of NACT is appealing. It
seems plausible that that NACT might compensate for these delays,
and enhance both local and systemic control, halt further tumour
progression in addition to reducing patient anxiety. However,
there is no evidence to support this approach. In contrast, this new
enthusiasm appears currently waning in other sites such as head
and neck and nasopharynx cancer where traditionally NACT has
been used (Garden, 2005).
With the aim of reducing systemic micrometastases, the use of
neoadjuvant combination chemotherapy using oxaliplatin and 5FU
before CRT has been explored in rectal cancer (Calvo et al, 2003;
Chau et al, 2005). A Spanish study (Calvo et al, 2003) explored a
short, intense induction regimen of oxaliplatin and 5FU (FOLFOX
4) before conventional CRT, which appeared to improve the
tumour downstaging when compared to historical results in their
unit previously achieved with CRT alone. This strategy of NACT
claims to achieve a 29% complete pathological response rate in
locally advanced rectal cancer. Studies from the UK have shown
that similar neoadjuvant drug combinations in locally advanced
rectal cancer can be delivered without apparently compromising
future compliance to CRT (Chau et al, 2003, 2005).
Not all clinically localised cancers can be cured by radiation
alone. Larger, more advanced cancers are more difficult to control
locally than smaller ones and require higher doses of radiation
(Fletcher, 1980; Perez et al, 1998). It is well recognised that factors
such as hypoxia, which are often a consequence of rapid tumour
growth have a negative impact on local control and survival from
radiation therapy (Fyles et al, 1998; Nordsmark and Overgaard,
2000). Additionally, patients with more advanced tumours also are
at a higher risk of systemic metastases. Hypoxia-driven cellular
mechanisms may also contribute to a poor outcome, producing a
more aggressive locoregional disease, and promotion of invasive
capacity and angiogenesis (Walenta et al, 2000; Brizel et al, 2001).
It has always been supposed that the anticancer effects of
radiotherapy are mediated through oxygen associated free radical
production (Hall, 2000). Others have stressed the importance of
the overall time factor in combined modality treatment of head
and neck cancer (Peters and Withers, 1997) in that accelerated
repopulation can occur for any clonogens surviving a therapeutic
intervention. Owing to this, novel treatment strategies have been
devised. These aim to improve local and distant control. A number
of biological rationales have been developed, including reducing
the duration of potential maximum cellular proliferation by
increasing the dose and intensity of treatment during the latter
part of radiotherapy, or the addition of concurrent chemotherapy.
An alternative strategy has been to use more intensive neoadjuvant
or postoperative adjuvant chemotherapy. Consequently, combina-
tions of sequential or concurrent chemotherapy and external beam
irradiation have been in clinical use since the 1980s.
For the purpose of this article, chemotherapy should be
considered as ‘neoadjuvant’ if it is administered as induction
before radiotherapy, ‘concurrent’ if administered during the
course of radiotherapy and ‘consolidation’ if delivered after
radiation or CRT. In this review, we aim to explore the advantages
and disadvantages of these separate approaches both in rectal
cancer and other disease sites.
MATERIALS AND METHODS
A literature search was performed using Medline and Cancerlit
over the period 1996–2005 supplemented by hand searching of
abstracts from the proceedings of the American Society of Clinical
Oncology meetings to provide evidence for this discussion. Several
keywords have been used which include synchronous, neo-
adjuvant, induction, concurrent, consolidation chemotherapy,
CRT, radiotherapy and cancer.
Neoadjuvant chemotherapy
Advantages There are many theoretical advantages to NACT,
which include the potential to eradicate distant micrometastases at
an early stage in the evolution of the disease, utilization of the
embryonic tumour blood supply and treatment of a fit patient,
before, not after the depredations of surgery. In contrast, in the
postoperative setting the patient is often unfit, and there is a
significant chance of hypoxia within surgical scars or any residual
disease. There is also evidence that the primary tumour without
metastatic disease may be more sensitive to chemotherapy than
metastatic lesions (Von Hoff et al, 1986; Maehara et al, 1990).
Tumour shrinkage with chemotherapy potentially allows
improved tumour vascularity. Theoretically, the consequences of
this are improved oxygenation and higher intratumoural levels of
cytotoxic drugs – although there is only scanty data to confirm this
hypothesis (Milas et al, 1995; Taghian et al, 2005). This is not just
an issue of the tumour getting smaller, since it would also be
expected that significant cell loss with cytotoxic chemotherapy
may lead to a reduction in oxygen consumption (Milas et al, 1995).
These factors of better oxygenation and improved drug access
from a lower interstitial pressure (Taghian et al, 2005) in turn may
enhance tumour sensitivity to chemotherapy or radiation. In
addition, in the clinic, oncologists endorse the use of NACT to
reduce the primary tumour volume and consequently reduce the
high-dose radiation volume. This change in field size can allow
avoidance of the tolerance dose for critical structures.
Randomised trials have established a well-defined role for NACT
before surgical resection both to promote resectability and to allow
more conservative surgery in primary breast cancer (Mauriac et al,
1991; Scholl et al, 1994; Makris et al, 1998; van der Hage et al, 2001;
Bear et al, 2003). However, these trials in breast cancer have shown
that there is no impact on survival whether the chemotherapy
schedule is delivered before or after surgery. This strategy of
NACT has also been used in head and neck cancer (The
Department of Veterans Affairs Laryngeal Cancer Study Group,
1991; Lefevre et al, 1996), where it has resulted in significant
downstaging of a locally advanced tumour, and allowed more
patients to undergo a curative resection (Spaulding et al, 1994).
However, the combination of NACT followed by radiotherapy was
found to be inferior to concomitant CRT for organ preservation
(Forrestiere et al, 2003).
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chemotherapy and radiotherapy at different times. First, the
interaction between chemotherapy and radiotherapy often gives
rise to such a marked increase in acute toxicity that it is necessary
to reduce the dose and intensity of chemotherapy. Neoadjuvant
chemotherapy may be associated with better compliance to
treatment, and enable full systemic doses of chemotherapy to be
delivered. In contrast, the effectiveness of adjuvant treatment in
the postoperative setting has frequently been compromised by
poor tolerance and marked dose reductions in oesophageal and
rectal cancer.
NACT may act in some ways as a selection manoeuvre. There
always exists a subset of patients with a very aggressive natural
history, who are likely to fail to respond to chemotherapy. The
delay before surgery means that patients who fail to respond
locally, progress and may develop metastatic disease (Rohatgi et al,
2005) or deteriorate because of excess toxicity, can be selected out.
These groups have no real possibility of benefit and can be spared
the rigours of surgery or radical CRT.
A major advantage of NACT lies in the ability to observe and
evaluate tumour clinical response during treatment. It is therefore
often argued that response is a good testing ground for novel
chemotherapy combinations, and that response to NACT can
define good and bad prognostic groups – although these patients
may well have a favourable outcome anyway. In contrast to crude
measures like size on CT scans, the use of sequential positron
emission tomography may define a major metabolic response to
CRT (Guillem et al, 2004), and offers the opportunity to predict a
better outcome in terms of overall survival. Failure to respond
enables the delivery of a noncross resistant chemotherapy in breast
cancer, as has been used in the Aberdeen neoadjuvant trial in
breast cancer (Smith et al, 2002). However, in rectal cancer
crossover studies at progression of first-line therapy have shown
low rates of response to second-line chemotherapy (Tournigand
et al, 2004).
Disadvantages Induction chemotherapy will delay the definitive
local treatment. Radiobiological evidence suggests that the
potential doubling time of clonogenic cells can reach their
maximum potential if cell loss is abolished (Kummermehr et al,
1992). Thus, by adding 9–12 weeks to the overall duration of
treatment with 3–4 cycles of induction chemotherapy, tumour cell
production could actually increase even if the volume of tumour
on CT scanning appears less (Withers et al, 1988). Other authors
have raised concerns regarding the time factor, and how
preoperative chemotherapy may fail to take into account radio-
biological principles of repopulation (Peters and Withers, 1997).
NACT can accelerate the kinetics of tumour proliferation in
residual cells, since it is observed that sequential responses from
multiple lines of chemotherapy become shorter in duration.
As it is recognised that only a proportion of patients will
respond to NACT, those who fail to respond in a large proportion
of the cells are more likely to develop resistant cells. This process
favours the selection of radio-resistant clones, and may reduce the
efficacy of subsequent radiotherapy. In addition, if neo-adjuvant
chemotherapy inhibits apoptotic pathways, then it may render
what are normally apoptosis prone tumour cells less sensitive to
radiation. It is also well recognised that chemotherapy may in
some tumours upregulate epidermal growth factor receptor
(EGFR) expression (De Pas et al, 2004), which in turn promotes
angiogenesis, affects stromal proliferation, and may make the
tumour more radio-resistant. Thus short-term response may not
improve long-term outcome.
In cervical cancer, at least seven randomised trials have
compared neoadjuvant cisplatin containing induction chemo-
therapy plus radiation therapy with radiation therapy alone
(Chauvergne et al, 1990; Souhami et al, 1991; Tattersall et al,
1992; Kumar et al, 1994; Tattersall et al, 1995; Sundfor et al, 1996;
Leborgne et al, 1997). These have consistently failed to show an
improvement in overall or disease-free survival. In two trials
(Souhami et al, 1991; Tattersall et al, 1992) results of NACT were
significantly worse. It has been conjectured that this is a result of
reducing compliance to the radiotherapy component and possibly
enhancing accelerated repopulation of resistant clones with
induction chemotherapy.
NACT especially in long courses (3–4 cycles) also may allow
time for these drug-resistant clones to migrate from the primary
site and seed distant or potential sanctuary sites. In small-cell lung
cancer, where high responses to chemotherapy are observed, there
is a significant increase in the incidence of brain metastases in
patients receiving late compared to early thoracic radiotherapy,
and a worse overall survival (Murray et al, 1993).
Finally, compliance to the CRT phase may be reduced if severe
toxicity is experienced with NACT (Table 1).
Concurrent chemotherapy
In rectal cancer there have been many different concurrent CRT
schedules evaluated in phase I/II studies. Most researchers have
used either a continuous infusion of 5FU (Rich et al, 1995), or the
oral fluoro-pyrimidines (Hoff et al, 2000; Dunst et al, 2002; Kim
et al, 2002; Dunst et al, 2004). Other more recent trials have
integrated oxaliplatin into the CRT schedule (Rosenthal et al, 2002;
Rodel et al, 2003; Glynne-Jones et al, 2004), and also irinotecan
(Michell et al, 2001; Kennedy et al, 2004; Hofheinz et al, 2005).
The evidence base in terms of randomised trials of concurrent
CRT in rectal cancer is limited. The North American standard of
care in rectal cancer is to deliver postoperative chemotherapy and
CRT to patients staged postoperatively as T3/4 or Nþ. This policy
has been defined within the NIH consensus statement in 1990
based on the results of two pivotal randomised American studies
(GTSG 7175 and NCCTG 79/47/51) (Gastrointestinal Tumor Study
Group, 1985; Krook et al, 1991). The NSABP RO2 study (Wolmark
et al, 2000), showed that the addition of radiotherapy produced
Table 1 Neoadjuvant chemotherapy
Potential advantages Potential disadvantages
Early treatment of micrometastases Increase in duration of chemotherapy
Tumour will have intact blood supply Delays definitive treatment
Delivery of full systemic doses Favours development of resistant clones
Better compliance to chemotherapy treatment May select radio-resistant clones
May enhance oxygenation and radio-responsiveness May allow distant/sanctuary site seeding
May allow radical RT if tumour shrinks May reduce compliance to chemoradiation
Potential for organ sparing if downstaged
Potential for curative resection if downstaged
Avoids surgery for resistant/rapidly progressive tumours
Response to chemo predictive of response to radiation
Response may define good/bad prognostic groups
Neoadjuvant chemotherapy before CRT
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ssignificantly less locoregional failure as a first event (8 vs 13% at 5
years) compared to adjuvant chemotherapy alone. However, the
addition of radiotherapy did not influence overall relapse-free or
disease-free survival.
A further European randomised trial of postoperative 5FU-
based CRT against surgery alone in Dukes B and C rectal cancer to
a dose of 46Gy demonstrated a significant improvement in local
control, disease-free survival and overall survival for postoperative
CRT (Tveit et al, 1997).
On the basis of this evidence, many mainland European
countries have extrapolated the North American approach to the
preoperative setting and deliver CRT to patients who are
considered T3/4 or Nþ on the basis of preoperative transrectal
ultrasound. In France in 1994, a national consensus statement
recommended the use of preoperative CRT in T3 and resectable T4
rectal cancer (Conference de consensus, Paris 1994).
A recent German phase III trial randomised 823 patients
between preoperative CRT and postoperative CRT (patients
received postoperative adjuvant chemotherapy in both arms of
this trial). This study convincingly showed an improved ther-
apeutic ratio for preoperative treatment. Local recurrence, acute
and late toxicity were all statistically significantly reduced with the
preoperative approach (Sauer et al, 2004). There was, however, no
difference in the distant metastases rate or overall survival.
Two recent large trials have (from the EORTC and FFCD
groups), have compared preoperative radiotherapy alone with
preoperative CRT (Bosset et al, 2005a,b; Gerard et al, 2005). The
former trial has also used a second randomisation to compare
postoperative adjuvant 5FU chemotherapy following CRT vs no
further treatment (Bosset et al, 2005a). Both trials demonstrated a
highly signigficant reduction in the risks of local recurrence, but
showed no impact on metastases, disease-free survival or overall
survival.
In addition two small randomised trials of CRT in the
postoperative adjuvant setting also support the view that
concurrent chemotherapy is the most effective strategy (Fountzilas
et al, 1999; Cafiero et al, 2003). The first paper questions the
additional advantage to consolidation chemotherapy following the
main strategy of concurrent CRT. In contrast the data from Cafiero
suggest that the beneficial results of concurrent CRT may not
apply if these modalities are administered sequentially rather than
concurrently.
Advantages Prolongation of overall radiotherapy time allows
accelerated repopulation. Concurrent CRT schedules therefore
appear more efficient and may well offer more advantage in terms
of locoregional control if our current hypotheses regarding
accelerated tumour cell proliferation are correct. It is recognised
that the rate of tumour growth is slower than the potential
doubling time of tumour cells reflecting the cell loss factor. Cell
production rates can be approximately 10 times faster than tumour
growth rates (Trott, 1999). Repopulation is probably accounted for
both by a decrease in the cell loss factor and in an increase in the
rate of proliferation of surviving tumour cells (Fowler, 1991). Many
consider that the increase in cellular repopulation relates both to
increase in tumour oxygen and also cellular density changes. The
advantage of the concurrent administration of radiotherapy and
chemotherapy is that it may prevent the tumour repopulating.
In non-small-cell lung cancer (NSCLC), randomised studies
comparing sequential vs concurrent treatment have shown an
advantage to the concurrent approach; perhaps not surprisingly,
there is an associated greater toxicity. Both Curran et al (2000) and
Furuse et al (1999), as well as a recent preliminary report (Choy
et al, 2002), have shown an advantage to early CRT followed by
consolidation chemotherapy in terms of median survival over both
induction followed by concurrent and sequential chemotherapy
and radiotherapy. Individual trials have also demonstrated an
overall survival benefit for concurrent CRT over sequential
chemotherapy and radiation or radiation alone in nasopharyngeal
cancer (NPC) of about 30% (Al-Sarraf et al, 1998; Chan et al, 2002;
Lin et al, 2003).
A recently reported phase III trial (Forrestiere et al, 2003)
randomised patients with locally advanced laryngeal cancer into
three study groups. The first group received induction chemo-
therapy with cisplatin plus 5FU 120h infusion every 3 weeks for 2–
3 courses depending on response followed by radical radiotherapy.
The second group received radiotherapy with concurrent admin-
istration of cisplatin at a dose of 100mgm
 2 on days 1, 22 and 43
but without any induction chemotherapy. The third group received
radiotherapy alone. A total of 540 patients were randomly assigned
to one of these three groups. Locoregional control was significantly
better with concurrent cisplatin and radiotherapy (78 vs 61% for
induction chemotherapy followed by radiotherapy). In addition
91% of patients who received induction chemotherapy were
metastasis-free compared to 92% of those who received concurrent
chemotherapy and radiotherapy. However, overall survival rates
were similar in all three groups. The study concludes that
radiotherapy with concurrent cisplatin should be the standard of
care for patients who wish to preserve their larynx. The routine use
of induction chemotherapy followed by radiotherapy in head and
neck cancer is therefore not supported by the results of this trial.
Concurrent chemotherapy potentially introduces systemic doses
of chemotherapy early at the same time as the intensive treatment
of the primary tumour. Early chemotherapy will hopefully stop
repopulation and downregulate any angiogenic mechanisms,
which in turn may help to prevent metastases. There is an obvious
potential that greater toxicity will result from concurrent
chemotherapy.
Disadvantages Concurrent chemotherapy may be associated with
a high risk of enhanced acute toxicity, in part because
chemotherapy may inhibit the ability of normal tissue to repair
the sublethal radiation induced damage. In order to avoid excess
toxicity, most clinicians have resorted to lower doses of
chemotherapy and a maximum of two drugs. However, lower
doses of chemotherapy imply less systemic effects on reducing
metastatic disease. An alternative strategy is to reduce the total
dose of radiotherapy, although this practice too has been criticised
on the grounds of delivering an inadequate dose. Concurrent
chemotherapy and radiotherapy may be associated with more
acute and dose limiting toxicity, and also more late toxicity
(Table 2).
Consolidation chemotherapy
A third strategy (consolidation chemotherapy) is to deliver
chemotherapy late in the process of radiotherapy or shortly after
its completion. The role of using a consolidation chemotherapy
schedule is currently being explored in the United Kingdom ACT
II trial in anal cancer where patients are randomised to two courses
of 5FU/cisplatin following the completion of CRT or no further
treatment (James and Meadows, 2003). This policy is also likely to
be explored in rectal cancer in a planned American ACOSOG
study.
Advantages Shrinking the tumour with radiotherapy may allow
improved tumour vascularity and facilitate high levels of cytotoxic
drugs reaching any remaining tumour cells. It is also possible that
the small percentage of clonogenic tumour cells that manage to
survive to the end of radiotherapy may be partially damaged but
more actively proliferating and may have increased susceptibility
to cytotoxic chemotherapy. In addition the high rate of failure in
terms of distant metastases, suggests that residual malignant cells
either in the primary site or elsewhere may require more effective
and additional systemic methods of elimination if cure is to be
achieved.
Neoadjuvant chemotherapy before CRT
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temically active chemotherapy in a consolidation phase is that this
strategy does not allow a response to be assessed in terms of
chemotherapy, and makes it difficult to decide later whether
further chemotherapy is required. In addition, toxicity from CRT
may compromise the dose intensity of consolidation chemo-
therapy.
A study from South Korea (Lee et al, 2002) enrolled patients
with Stages II and Stage III rectal cancer following TME surgery.
This study aimed to investigate whether early, as opposed to late,
postoperative radiotherapy with chemotherapy was the optimal
sequence. Radiotherapy started on Day 1 on the first cycle of
chemotherapy in the early RT group and Day 1 of the third cycle of
chemotherapy in the late RT arm. With a median follow-up of 37
months, 61 (22%) of the 274 eligible patients had experienced a
recurrence of their rectal cancer, 23 in the early radiotherapy
group vs 38 in the late radiotherapy group. The 4-year rate of
disease-free survival was 81% for early radiotherapy and 71% for
late radiotherapy. Both distant metastases and local regional
recurrence appeared to show a trend towards being less frequent
for early radiotherapy (15 vs 22% and 2 vs 6%, respectively).
However, the 4-year overall survival was similar in both groups (84
vs 82%). This study seems to confirm the hypothesis that early
radiotherapy may be advantageous, and mirrors data suggesting
an improved outcome is obtained from early radiotherapy in
studies of small-cell lung cancer and NPC (Table 3).
DISCUSSION
The use of NACT before CRT in other disease sites remains
controversial. Four meta-analyses have examined data from the
published phase III trials in head and neck cancer, and all have
concluded that concurrent rather than neoadjuvant induction
chemotherapy regimens lead to improved survival (Stell, 1992;
Munro, 1995; El-Sayed and Nelson, 1996; Pignon et al, 2000). The
benefit appears to be 7% at 2 years and 8% at 5 years. Two of the
meta-analyses (El-Sayed and Nelson, 1996; Pignon et al, 2000)
showed no survival advantage to NACT.
Despite the enrolment of large numbers of patients with head
and neck cancer in studies testing chemotherapy in the induction
setting, and concurrently with radiation, only synchronous CRT
has changed outcomes. There are no data to suggest that induction
chemotherapy improves local control (Forrestiere et al, 2003).
Neoadjuvant induction chemotherapy has shown a benefit in terms
of organ preservation in head and neck cancer, but not in terms of
overall survival. It remains unclear whether organ preservation is
achieved by effective downstaging of the tumour or by selecting
patients who are potentially curable by radiation alone. This is not
necessarily the same as induction chemotherapy being able to
predict the response to subsequent radiotherapy. The routine use
of induction chemotherapy followed by radiotherapy in head and
neck cancer is therefore not supported by the results of trials.
There is evidence that NACT may improve outcome in terms of
disease-free or overall survival is strongest when NACT is
administered before surgical resection (Law et al, 1997; MRC,
2002; Allum et al, 2003); although three metanalyses in oesopha-
geal cancer (Malthaner and Fenlon, 2001; Urschel et al, 2002;
Malthaner et al, 2004) failed to show a survival benefit for NACT
before surgery. Neoadjuvant chemotherapy did not change the
number or pattern of local distant or regional recurrence. This
advantage does not appear to extend to all patients. Some subsets
of patients with an excellent clinical (and pathological) response to
NACT appear to have an extended survival time, but despite this
observation, overall survival time of the whole group has usually
failed to improve.
In NSCLC, the CALGB group established that two cycles of
induction chemotherapy using cisplatin and vinblastine followed
by radiotherapy to the chest increases median survival time when
compared to radiotherapy alone. (Dillman et al, 1996; Sause et al,
Table 2 Concurrent chemotherapy (chemoradiation – CRT)
Potential advantages Potential disadvantages
Early treatment of micrometastases Delivery of less than full systemic doses
May prevent repopulation during radiotherapy Worse compliance to chemotherapy treatment
Tumour will have intact blood supply More acute toxicity?
Potential for organ sparing if downstaged More late toxicity?
Potential for curative resection if downstaged
Avoids surgery for resistant/progressive tumours
Response may define good/bad prognostic groups
Trials show improved local control
Trials show reduced rates of metastatic disease
Table 3 Consolidation chemotherapy in addition to chemoradiation (CRT)
Potential advantages Potential disadvantages
Early treatment of micrometastases Does not allow assessment of response to chemo
May prevent repopulation during radiotherapy Worse compliance to chemotherapy treatment
Tumour will have intact blood supply Delivery of less than full systemic doses?
May enhance oxygenation and chemo-responsiveness More acute toxicity?
Delivery of full systemic doses? More late toxicity?
Cells may be more sensitive to chemotherapy
Potential for organ sparing if downstaged
Potential for curative resection if downstaged
Avoids surgery for resistant/progressive tumours
Response may define good/bad prognostic groups
Trials show improved local control from CRT
Trials show reduced rates of metastatic disease
Trials show early radiotherapy is more effective
Neoadjuvant chemotherapy before CRT
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rates of systemic failure, it has failed to improve local control. A
meta-analysis has shown an advantage for cisplatin-based induc-
tion chemotherapy followed by radiotherapy over radiotherapy
alone (Gordon and Vokes, 1999) but an advantage for NACT
followed by CRT over CRT alone has not been observed. When the
two strategies have been directly compared, concurrent chemo-
therapy and radiotherapy appears statistically superior to induc-
tion chemotherapy although at the price of more severe acute
toxicity (Furuse et al, 1999; Curran et al, 2000, 2003).
In bladder cancer, it is possible that there is a small advantage
for NACT before cystectomy (Grossman et al, 2003). However, in
muscle invasive bladder cancer, the only trial that has compared
neoadjuvant and concurrent CRT (RTOG 89-03) has not shown
benefit in survival (Shipley et al, 1998).
Ian Tannock’s first law of chemotherapy states: ‘Tumour
response is not an endpoint of patient benefit’ (Tannock et al,
1996). There is no evidence that increasing the rate of a clinical or
pathological complete response consistently correlates with an
increase in disease-free and overall survival. By adding 12 weeks to
the overall duration of treatment with 3–4 cycles of induction
chemotherapy, tumour cell production could actually increase
even if the volume of tumour on CT scanning appears less.
Resistance to chemotherapy probably occurs earlier than evidence
of tumour progression would lead us to believe (Smith et al, 2002).
If NACT is administered before CRT, it may be appropriate to
consider using a noncross resistant combination rather than the
same drug, for example, oxaliplatin in both schedules. This
strategy might overcome the limit of resistant clones developing
during concurrent CRT.
In unresectable rectal cancer, or borderline resectable cancers
where the circumferential margin is unsafe on preoperative MRI,
the most important component is concurrent CRT. In contrast,
NACT before surgery for resectable cancers might reduce the risk
of subsequent metastatic disease, and is not so concerned with
local control. Hence, this is a suitable question to be addressed in
future research programmes if surgery alone is the primary
treatment. Therefore, we need better initial patient selection, and
we need a quick, valid and reliable method of assessing metabolic
response or – perhaps better still – resistance to chemotherapy.
For locally advanced rectal cancer, current evidence suggests
that preoperative CRT provides optimal locoregional control.
However, distant failure remains common. The role of adjuvant
chemotherapy either before or following CRT in improving
disease-free or overall survival has yet to be established, despite
evidence that response to induction chemotherapy may predict
response to subsequent radiotherapy.
However, experience from other sites (multiple trials in head
and neck cancer, NPC, NSCLC, small-cell lung cancer, and cervical
cancer) does not support the routine use of NACT either as an
alternative, or as additional benefit to CRT. Neoadjuvant
chemotherapy does not appear to enhance local control over
concurrent CRT or radiotherapy alone. Although there are some
data to suggest a reduction in the risk of metastatic disease, the
majority of these trials show an advantage for the combination of
concurrent chemotherapy and radiotherapy rather than the
sequential or induction approach.
CONCLUSIONS
Our conclusion is that concurrent CRT with early positioning
of radiotherapy therefore appears the best option in all
disease sites where radiation is the primary local therapy.
Neoadjuvant chemotherapy before CRT or radiation in rectal
cancer should be used with caution, and only in the context of
clinical trials. If NACT is used in this group of patients, a noncross
resistant combination is recommended rather than the same
drug, for example, oxaliplatin in both schedules. Also the
observation of major clinical and pathological downstaging should
not obviate the requirement for CRT either pre operatively or post
operatively as there will remain a significant risk of local
recurrence.
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